Trial Profile
Assessment of the safety, tolerance, and immunogenicity of EG-HPV (human papillomavirus vaccine) in healthy male adult volunteers: A double-blinded, randomized, adjuvant vehicle-controlled trial
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent EyeGene (Primary) ; Aluminium-hydroxide/CIA-05; CIA-05
- Indications Cervical cancer; Human papillomavirus infections; Penile cancer
- Focus Adverse reactions
- Sponsors EyeGene
- 25 Jan 2013 New trial record